Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN.

Clin Cancer Res. 2011 Sep 1;17(17):5674-85. doi: 10.1158/1078-0432.CCR-11-0432. Epub 2011 Jul 13.

2.

Blockade of Jagged/Notch pathway abrogates transforming growth factor β2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells.

Chen X, Xiao W, Liu X, Zeng M, Luo L, Wu M, Ye S, Liu Y.

Curr Mol Med. 2014 May;14(4):523-34. Review.

PMID:
24694299
3.

Notch signaling in serous ovarian cancer.

Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR.

J Ovarian Res. 2014 Nov 4;7:95. doi: 10.1186/s13048-014-0095-1. Review.

4.

Targeting the tumour microenvironment in ovarian cancer.

Hansen JM, Coleman RL, Sood AK.

Eur J Cancer. 2016 Mar;56:131-43. doi: 10.1016/j.ejca.2015.12.016. Epub 2016 Feb 3. Review.

5.

The role of Notch signalling in ovarian angiogenesis.

Xie Q, Cheng Z, Chen X, Lobe CG, Liu J.

J Ovarian Res. 2017 Mar 11;10(1):13. doi: 10.1186/s13048-017-0308-5. Review.

6.

Signaling pathways governing tumor angiogenesis.

Sakurai T, Kudo M.

Oncology. 2011;81 Suppl 1:24-9. doi: 10.1159/000333256. Epub 2011 Dec 22. Review.

PMID:
22212932
7.

Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

Kurzeder C, Sauer G, Deissler H.

Curr Cancer Drug Targets. 2006 May;6(3):207-27. Review.

PMID:
16712458
8.

Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway.

Geissler K, Zach O.

Ann Hematol. 2012 May;91(5):645-669. doi: 10.1007/s00277-012-1435-0. Epub 2012 Mar 16. Review.

PMID:
22418742
9.

Targeting angiogenesis in the pathological ovary.

Duncan WC, Nio-Kobayashi J.

Reprod Fertil Dev. 2013;25(2):362-71. doi: 10.1071/RD12112. Review.

PMID:
22951108
10.

The notch ligand JAGGED1 as a target for anti-tumor therapy.

Li D, Masiero M, Banham AH, Harris AL.

Front Oncol. 2014 Sep 25;4:254. doi: 10.3389/fonc.2014.00254. eCollection 2014. Review.

11.

Hedgehog signaling: networking to nurture a promalignant tumor microenvironment.

Harris LG, Samant RS, Shevde LA.

Mol Cancer Res. 2011 Sep;9(9):1165-74. doi: 10.1158/1541-7786.MCR-11-0175. Epub 2011 Jul 20. Review.

12.

Tumor microenvironment: The culprit for ovarian cancer metastasis?

Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, Yang H, Feng M, Xuan Y, Yang Y, Lei L, Wang C, Yi T, Zhao X, Wei Y, Zhou S.

Cancer Lett. 2016 Jul 28;377(2):174-82. doi: 10.1016/j.canlet.2016.04.038. Epub 2016 Apr 27. Review.

PMID:
27131957
13.

Therapeutic strategies for targeting the ovarian tumor stroma.

Ko SY, Naora H.

World J Clin Cases. 2014 Jun 16;2(6):194-200. doi: 10.12998/wjcc.v2.i6.194. Review.

14.

The role of the tumor stroma in ovarian cancer.

Davidson B, Trope CG, Reich R.

Front Oncol. 2014 May 13;4:104. doi: 10.3389/fonc.2014.00104. eCollection 2014. Review.

Supplemental Content

Support Center